Levetiracetam Injection
Product Images NDC 70069-846

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70069-846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Somerset Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam-1000mg-100ml-10mg-ml-alu-pouch-label (Levetiracetam 1000mg 100ml 10mg mL Alu Pouch Label)

Label for Levetiracetam in 0.75% Sodium Chloride Injection, 1000 mg/100 mL (10 mg/mL) intravenous infusion by Somerset Therapeutics, LLC. The single-dose 100 mL bag is manufactured by Caplin Steriles in India and includes instructions for opening, storage recommendations, and cautions regarding use and handling.*

FDA Label Image

Levetiracetam-1000mg-100ml-10mg-ml-bag-label (Levetiracetam 1000mg 100ml 10mg mL Bag Label)

Label for Levetiracetam in 0.75% Sodium Chloride Injection, 1000 mg/100 mL (10 mg/mL) intravenous infusion. The label indicates single-dose dual port bag packaging, manufactured by Somerset Therapeutics, LLC, Somerset, NJ. Storage and usage instructions are included, along with a barcode and NDC number 70069-846-01.*

FDA Label Image

Levetiracetam-1500mg-100ml-15mg-ml-alu-pouch-label (Levetiracetam 1500mg 100ml 15mg mL Alu Pouch Label)

Label for Levetiracetam in 0.54% Sodium Chloride Injection, 1500 mg/100 mL (15 mg/mL), for intravenous infusion. The single-dose injection is manufactured by Caplin Steriles for Somerset Therapeutics LLC. The label includes usage instructions, storage recommendations, and cautions. Barcode and manufacturing details are also displayed.*

FDA Label Image

Levetiracetam-1500mg-100ml-15mg-ml-bag-label (Levetiracetam 1500mg 100ml 15mg mL Bag Label)

Label for Levetiracetam in 0.54% Sodium Chloride Injection, 1500 mg/100 mL (15 mg/mL) intravenous infusion by Somerset Therapeutics, LLC. The label includes dosage concentration, NDC 70069-847-01, instructions for infusion over 15 minutes, storage recommendations, and manufacturer information. The product is a single-dose dual port bag containing 100 mL.*

FDA Label Image

Levetiracetam-500mg-100ml-5mg-ml-alu-pouch-label (Levetiracetam 500mg 100ml 5mg mL Alu Pouch Label)

Label for Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL (5 mg/mL) intravenous infusion by Somerset Therapeutics LLC. The label includes instructions for infusion, storage recommendations, manufacturer details, and a barcode. The container is a single-dose dual port bag with an aluminum overwrap, labeled for sterile use.*

FDA Label Image

Levetiracetam-500mg-100ml-5mg-ml-bag-label (Levetiracetam 500mg 100ml 5mg mL Bag Label)

Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL (5 mg/mL) intravenous infusion in a 100 mL single-dose dual port bag. Label includes NDC 70069-845-01 and is manufactured for Somerset Therapeutics, LLC. Storage and usage instructions are detailed on the label.*

FDA Label Image

Levetiracetam-caplin-logo (Levetiracetam Caplin Logo)

FDA Label Image

Figure-1 (Levetiracetam Figure 1)

A bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows the percentage of patients, with values ranging from 0% to 45%. The graph includes sample sizes (N) for each group and indicates statistical significance of Levetiracetam groups versus placebo.*

FDA Label Image

Figure-2 (Levetiracetam Figure 2)

Bar graph comparing the percentage of patients among three groups: Placebo (111 patients), Levetiracetam 1000 mg/day (106 patients), and Levetiracetam 2000 mg/day (105 patients). The graph indicates progressively higher percentages of patients for each dose level, with statistical significance noted versus placebo.*

FDA Label Image

Figure-3 (Levetiracetam Figure 3)

A bar graph comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The y-axis shows percentage of patients from 0% to 45%. Placebo group (N=104) shows about 14.4%, and Levetiracetam group (N=180) shows about 39.4%, with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

Figure-4 (Levetiracetam Figure 4)

A bar graph comparing the percentage of patients on placebo versus Levetiracetam, showing 45.2% for placebo (N=84) and 72.2% for Levetiracetam (N=79), with an indication of statistical significance between groups.*

FDA Label Image

Str (Levetiracetam Structure)

Chemical structure of Levetiracetam. The diagram shows the molecular arrangement including a pyrrolidone ring, an ethyl group, an amide group, and hydrogen atoms connected to a central carbon atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.